AC
IBRX icon

AXQ Capital’s ImmunityBio IBRX Stock Holding History

AXQ Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Buy
34,250
+488
+1% +$3.34K 0.03% 637
2025
Q4 		$66.8K Sell
33,762
-37,538
-53% -$85K 0.02% 681
2025
Q3 		$175K Buy
71,300
+51,678
+263% +$133K 0.07% 471
2025
Q2 		$51.8K Buy
19,622
+4,948
+34% +$13.3K 0.02% 539
2025
Q1 		$44.2K Buy
+14,674
New +$44.5K 0.02% 470
2024
Q1 		– Sell
-12,400
Closed -$62.2K – 754
2023
Q4 		$62.2K Buy
+12,400
New +$38.9K 0.02% 618
2023
Q1 		– Sell
-16,407
Closed -$83.2K – 551
2022
Q4 		$83.2K Buy
+16,407
New +$90.1K 0.06% 304

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AXQ Capital's IBRX Position: Q1 2026 in Review

AXQ Capital increased its ImmunityBio (IBRX) stake by 1.4% in Q1 2026, buying an estimated $3.34K and bringing the position to 34,250 shares worth $263K. The position accounts for 0.03% of the portfolio, ranked #637.

AXQ Capital first reported a position in IBRX in Q4 2022 and has held it in 7 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • AXQ Capital held 34,250 shares of ImmunityBio worth $263K as of Q1 2026.
  • AXQ Capital bought 488 ImmunityBio shares in Q1 2026, an estimated $3.34K.
  • ImmunityBio made up 0.03% of AXQ Capital's portfolio in Q1 2026, its #637 holding.
  • AXQ Capital first reported a position in ImmunityBio in Q4 2022 and has held it in 7 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.